"One stone hitting multiple targets!"

Apabetalone is not the first drug to elicit widespread transcriptional changes or to have multiple mechanisms of action.

One contemporary example is Amarin's omega-3 drug Vascepa (icosapent ethyl). It does far more than just lower plasma triglycerides; many other mechanisms of action. But a couple of better recent comparisons are Intercept's FXR agonist Ocaliva (obeticholic acid) and Kowa's PPAR alpha agonist Permafibrate. FXR and PPARs are just a couple of examples of transcription factors that are expressed in multiple tissues and elicit a number of transcriptional changes upon activation. 

These are just a few quick examples but there are many others. Did they get special treatment? If not, why should apabetalone?

BDAZ